Scientists test Two-Pronged attack on advanced cancers
NCT ID NCT01445509
Summary
This study aimed to find the safest dose for using two existing cancer drugs, dasatinib and bevacizumab, together. It involved 50 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to understand the side effects of this drug combination and see if it could help control cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.